This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is a Beat in Store for Dynavax (DVAX) This Earnings Season?
by Zacks Equity Research
Dynavax (DVAX) is actively pursuing development of coronavirus vaccine through collaborations. Investors are likely to focus on progress of vaccine programs on Q2 earnings call.
How Damaging Will Coronavirus be for AbbVie (ABBV) Q2 Earnings?
by Zacks Equity Research
Investor focus is likely to be on the impact of the coronavirus outbreak on AbbVie's (ABBV) performance when it reports second-quarter results.
Why Earnings Season Could Be Great for Pfizer (PFE)
by Zacks Equity Research
Pfizer (PFE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Markets Remain Calm But More Data and Earnings are Coming
by David Borun
Equities trend sideways as we wait for Congress and 30% of the S&P is set to report results.
Top Research Reports for Facebook, Verizon & Pfizer
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Facebook (FB), Verizon Communications (VZ) and Pfizer (PFE).
Will Coronavirus Woes Impact Gilead's (GILD) Q2 Earnings?
by Zacks Equity Research
Investors will focus on the HIV franchise's performance and the uptake of Yescarta along with updates on experimental coronavirus treatment, when Gilead (GILD) reports second-quarter 2020 results.
What's in the Cards for Glaxo (GSK) This Earnings Season?
by Zacks Equity Research
Glaxo's (GSK) Vaccines and Respiratory segments are likely to have driven second-quarter sales. Results will provide clarity on the impact of coronavirus on the company's business.
Amgen (AMGN) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the extent of the impact of the coronavirus outbreak on Amgen's (AMGN) performance when it reports second-quarter results.
What's in Store for AstraZeneca (AZN) This Earnings Season?
by Zacks Equity Research
AstraZeneca's (AZN) second-quarter results are expected to reflect the impact of new drug sales. However, the impact of coronavirus pandemic remains to be seen.
Pharma Stock Roundup: NVS, RHHBY Earnings, AZN, PFE Coronavirus Vaccine Early Data
by Kinjel Shah
Pfizer (PFE) and AstraZeneca (AZN) announce early data on their coronavirus vaccine candidates. Novartis (NVS) and Roche (RHHBY) announce second-quarter results.
3 Strong Dividend Stocks to Buy Now for Income & Coronavirus Growth
by Benjamin Rains
Let's dive into three stocks that are projected to grow during the pandemic that also provide solid income through dividends...
Will Pfizer's (PFE) BioPharma Unit Drive Its Q2 Earnings?
by Zacks Equity Research
In Pfizer's (PFE) Biopharma unit, oncology sales are likely to have risen in the second quarter, while in non-oncology, Eliquis alliance revenues are likely to have supported the top line.
The Zacks Analyst Blog Highlights: AstraZeneca, BioNTech, Pfizer, Cimarex Energy, Diamondback Energy, Centennial Resource Development and Bonanza Creek Energy
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AstraZeneca, BioNTech, Pfizer, Cimarex Energy, Diamondback Energy, Centennial Resource Development and Bonanza Creek Energy
Stock Market News for Jul 23, 2020
by Zacks Equity Research
Wall Street closed higher on Wednesday buoyed by good news from coronavirus treatment front and possible injection of fresh stimulus by the U.S. government.
Pfizer (PFE) Looks Good: Stock Adds 5.1% in Session
by Zacks Equity Research
Pfizer (PFE) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Earnings Data Deluge
by Zacks Equity Research
Earnings Data Deluge.
Big Day for Q2 Earnings, U.S. Spends $1.95B on Pfizer Drug
by Mark Vickery
Q2 earnings season really hits the accelerator today; it's the single-biggest day of earnings reports for the quarter so far.
The Zacks Analyst Blog Highlights: AstraZeneca, Pfizer, Moderna, Vaxart and Novovax
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AstraZeneca, Pfizer, Moderna, Vaxart and Novovax
Pfizer (PFE) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Pfizer (PFE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Small Biotechs in Focus on Promising Coronavirus Vaccine Data
by Zacks Equity Research
Pfizer (PFE) and AstraZeneca (AZN) announce promising data from early-stage coronavirus vaccine studies. Here we discuss three leading biotechs with potential to recshare price gains.
Stock Market News for Jul 21, 2020
by Zacks Equity Research
U.S. stock markets closed higher on Monday as the tech rally resumed after the gap of a week.
Can Pfizer (PFE) Deliver a Beat in Coronavirus-Hit Q2 Earnings?
by Zacks Equity Research
Investor focus is likely to be on the extent of the impact of the coronavirus outbreak on Pfizer's (PFE) performance when it reports second-quarter results.
Pfizer (PFE) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $36.50, marking a +0.69% move from the previous day.
Top and Flop ETFs to Start Third Quarter
by Sweta Killa
We have highlighted ETFs from the best and worst zones to start the third quarter.
Biogen (BIIB) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the extent of the impact of the coronavirus outbreak on Biogen's (BIIB) second-quarter earnings.